Primary Care Management of Pulmonary Embolism

Apple Podcasts , SpotifyListen Here

Guidelines have recommended outpatient management for patients with low-risk pulmonary embolism (PE) for many years. Despite this, few patients in the US diagnosed with acute PE are discharged from the Emergency Department (Westafer et al). Little is known about the course of patients managed exclusively or primarily in the outpatient setting. In this study, Vinson and colleagues describe the nature and course of patients diagnosed with pulmonary embolism in the primary care setting.

Vinson DR, Hofmann ER, Johnson EJ, Rangarajan S, Huang J, Isaacs DJ, Shan J, Wallace KL, Rauchwerger AS, Reed ME, Mark DG; PEPC Investigators of the KP CREST Network. Management and Outcomes of Adults Diagnosed with Acute Pulmonary Embolism in Primary Care: Community-Based Retrospective Cohort Study. J Gen Intern Med. 2022 Jan 12. doi: 10.1007/s11606-021-07289-0. Epub ahead of print. PMID: 35020167.

Pulmonary Embolism Diagnosis Update

Apple Podcasts , SpotifyListen Here

The diagnostic algorithm for pulmonary embolism (PE) has evolved over the past few years to include probability or risk-adjusted D-dimer. The YEARS algorithm includes an elevated D-dimer threshold for some risk groups and has been found to be safe and reduce imaging in several studies, including in pregnant patients. Now, this multicenter trial by Freund et al evaluates the use of YEARS and age-adjusted D-dimer compared with an age-adjusted approach alone.

Freund Y, Chauvin A, Jimenez S, Philippon AL, Curac S, Fémy F, Gorlicki J, Chouihed T, Goulet H, Montassier E, Dumont M, Lozano Polo L, Le Borgne P, Khellaf M, Bouzid D, Raynal PA, Abdessaied N, Laribi S, Guenezan J, Ganansia O, Bloom B, Miró O, Cachanado M, Simon T. Effect of a Diagnostic Strategy Using an Elevated and Age-Adjusted D-Dimer Threshold on Thromboembolic Events in Emergency Department Patients With Suspected Pulmonary Embolism: A Randomized Clinical Trial. JAMA. 2021 Dec 7;326(21):2141-2149. doi: 10.1001/jama.2021.20750. PMID: 34874418; PMCID: PMC8652602.

Bougie Vs Stylet for Endotracheal Intubation

Apple Podcasts , SpotifyListen Here

A single-center randomized trial in 2018 by Driver et al found an incredible 98% first-pass success for endotracheal intubation in the group randomized to a structured bougie-first approach, compared with 87% in those randomized to stylet. In this podcast, we review a multi-center study by Driver et al examining bougie vs stylet in a wider array of emergency departments and intensive care units.

Subsegmental Pulmonary Embolism

Apple Podcasts , SpotifyListen Here

Subsegmental pulmonary embolism (SSPE) is a controversial entity as they have uncertain clinical significance. As a result, the Chest and ACEP guidelines state that a very select group of patients with isolated SSPE and no deep vein thrombosis may be managed with surveillance rather than anticoagulation. In this podcast, we review SSPE and a new prospective study by Le Gal and colleagues evaluating outcomes after withholding anticoagulation in patients with subsegmental pulmonary embolism (SSPE).

COVID-19 mRNA vaccine ages 5-11

Apple Podcasts , SpotifyListen Here

On November 2, 2021, the US CDC Advisory Council on Immunization Practices recommended the Pfizer-BioNTech mRNA covid-19 vaccine for children ages 5-11. In this podcast we review the data in the Pfizer briefing document to the FDA as well as that presented at the ACIP meeting.

References for myocarditis: Witberg et al NEJM Oct 2021, Mevorach et al. NEJM Oct 2021

updated 11/1/2021

https://www.nejm.org/doi/full/10.1056/NEJMoa2110737

COVID-19 Boosters

Apple Podcasts , SpotifyListen Here

On September 24, 2021, the United States’ CDC made recommendations on who should or may receive a COVID-19 vaccine booster. These recommendations overstepped the vote made by the CDC’s Advisory Committee on Immunization Practices (ACIP), who voted against the recommendation that those 18-64 who have occupational exposure may receive a booster vaccine. In this podcast, we discuss the current evidence as of September 24, 2021 on boosters as well as the evidence-based risk-benefit analysis from the CDC ACIP meeting. Jeremy’s insights can be found at Inside Medicine.

First, the data presented from Pfizer is minimal and involves a total of 312 individuals who received boosters. We have no insight into effectiveness based on this.

In Israel, boosters were available to those ≥60 who completed the series ≥5 months prior beginning at the end of July. Bar-On et al report on this natural experiment.

The data presented at the CDC ACIP meeting can be found in the presentation slides available here.

Pulmonary Embolism Risk Stratification – Right Ventricular Dysfunction

Apple Podcasts , SpotifyListen Here

In this podcast, we review pulmonary embolism (PE) risk stratification and dive into the use of right ventricular dysfunction as a predictor of mortality. We highlight a patient-level meta-analysis by Becattini et al and discuss guidelines on PE risk stratification.

European Society of Cardiology Guidelines (2019)
American College of Emergency Physicians (ACEP) Venous Thromboembolism Guidelines (2018)
Becattini et al
Becattini et al